Division of General Internal Medicine, Mayo Clinic, Rochester, MN, USA.
Division of General Internal Medicine, Mayo Clinic, Rochester, MN, USA.
Clin Nutr. 2018 Aug;37(4):1181-1185. doi: 10.1016/j.clnu.2017.05.009. Epub 2017 May 17.
BACKGROUND & AIMS: Ethanol lock therapy (ELT) has been shown to reduce the rate of catheter-related bloodstream infection (CRBSI) in high-risk home parenteral nutrition (HPN) patients. The aim of this study was to determine whether ELT therapy for all patients newly started on HPN would reduce the incidence of CRBSI.
This study was a prospective, double-blind, randomized controlled trial that was carried out from July 2014 to April 2016. The study participants were patients newly started on HPN, and they were randomly assigned to either treatment with ELT or our current standard of care with saline heparin locks. The primary outcome was occurrence of CRBSI.
Thirty eight patients that were newly started on HPN were randomized to either treatment with ELT (n = 18) or to our current standard of care with heparin locks (n = 20). Four patients in the ELT group and one patient in the control arm had a CRBSI (p = 0.17). No significant adverse side effects were noted during the study.
This study did not show improvement in the rate of CRBSI with ELT in all patients started on HPN. ELT therapy may be most helpful to reduce in CRBSI in high-risk HPN patients, but further studies with a randomized control trial design of high-risk patients are needed to further clarify this important issue in HPN patients. The study was registered at clinicaltrials.gov prior to patient enrollment (NCT02227329).
乙醇封管疗法(ELT)已被证明可降低高危家庭肠外营养(HPN)患者导管相关血流感染(CRBSI)的发生率。本研究旨在确定对所有新开始接受 HPN 的患者进行 ELT 治疗是否会降低 CRBSI 的发生率。
这是一项前瞻性、双盲、随机对照试验,于 2014 年 7 月至 2016 年 4 月进行。研究对象为新开始接受 HPN 的患者,他们被随机分配接受 ELT 治疗或我们目前的生理盐水肝素封管标准治疗。主要结局为 CRBSI 的发生。
38 名新开始接受 HPN 的患者被随机分配接受 ELT 治疗(n=18)或我们目前的肝素封管标准治疗(n=20)。ELT 组有 4 名患者和对照组有 1 名患者发生 CRBSI(p=0.17)。在研究过程中未观察到明显的不良反应。
本研究未显示 ELT 治疗可提高所有开始接受 HPN 的患者的 CRBSI 发生率。ELT 治疗可能对降低高危 HPN 患者的 CRBSI 最有帮助,但需要进一步设计高危患者的随机对照试验来进一步阐明 HPN 患者中的这一重要问题。该研究在患者入组前在 clinicaltrials.gov 上进行了注册(NCT02227329)。